Spotlight: Healthcare Pricing & Financing

Welcome to ‘Healthcare Pricing & Financing’ – a Spotlight from The Evidence Base.

Here, we feature conference coverage, expert insights, news, journal articles and more to help you stay up-to-date with the latest discussions surrounding the big issues in pricing for therapies and the delivery of healthcare.

Read our coverage of the 2023 World EPA Congress, Amsterdam, The Netherlands:

World EPA Congress 2023: Editor’s round-up of Day 1

World EPA Congress 2023: Editor’s round-up of Day 2

World EPA Congress 2023: Editor’s round-up of Day 3

Read Expert Insights, covering healthcare pricing, published at The Evidence Base:

Impact of the Inflation Reduction Act on drug development and patients: an interview with Jason Spangler, Innovation and Value Initiative

Impact of the Inflation Reduction Act on US health care: an interview with Corey Ford and Kimberly Westrich, Xcenda

Why we need a patient-centric pricing perspective: an interview with Giovanny Leon, Novartis AG

Using RWE to benefit pricing and patient access: an interview with Ulf Staginnus, Blueprint Medicines, Switzerland

Ask the Experts: valuing new pharmaceuticals and sharing this value

Get in touch to discuss the opportunities available to share your expertise, contribute to this theme or to become a theme sponsor.

Discover more from The Evidence Base here

Drug Price Negotiation Program

PhRMA joins legal battle against Medicare drug pricing provisions in the Inflation Reduction Act

Inflation Reduction Act in numbers. smart prices act CMS Medicare

The Inflation Reduction Act in numbers: estimating the impact of implementing Medicare drug pricing policies on the US healthcare ecosystem

Medicare Part B prescription drugs

CMS expands lists of Part B prescription drugs subject to the Medicare Prescription Drug Inflation Rebate Program

Merck IRA lawsuit

Merck files lawsuit against US government over Medicare Drug Price Negotiation Program – will others follow?

Medical pills on one hundred dollar bills

The debate over QALYs in US drug value assessments continues

What next for QALYs in US drug value assessments?

Eisai communicate how they are pricing lecanemab for the treatment of Alzheimer’s disease in the US

As public R&D funding surges, so do drug costs

ISPOR 2023

ISPOR 2023: first look at the newly announced program

BioMarin’s ROCTAVIAN™ gene therapy for adults with severe hemophilia A: substantial cost saving per patient predicted in ICER analysis

Deloitte’s 2022 study: RWE’s evolution into a true end-to-end capability

Find articles published in the Journal of Comparative Effectiveness Research

A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications

Cost standard set program: moving forward to standardization of cost assessment based on clinical condition

The next generation of rare disease drug policy: ensuring both innovation and affordability

Potential policy reforms to strengthen the accelerated approval pathway

Evidence-based public policy making for medicines across countries: findings and implications for the future

Cornerstones of ‘fair’ drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals

Pharmaceutical pricing benchmarks: governmental versus private sector

Can real-world evidence save pharma US$1 billion per year? A framework for an integrated evidence generation strategy

Policy perspectives on alternative models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit

Ability to pay for medication: a clustering analysis of 1404 patients with the Patient Financial Eligibility Tool

Willingness to pay for medical treatments in chronic diseases: a multicountry survey of patients and physicians

A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions

Real-world evidence for coverage decisions: opportunities and challenges

Indication-specific pricing of pharmaceuticals in the US healthcare system